November 11, 2017
1 min read

Surgical margins predict survival in primary pleomorphic liposarcoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

WAILEA, Hawaii — Negative surgical margins correlated with improved long-term survival among patients with primary pleomorphic liposarcoma, according to study results presented at Connective Tissue Oncology Society Annual Meeting.

“This underscores the importance of proper sarcoma surgery in the setting of the primary disease in this rare histologic subtype,” Joseph G. Crompton, MD, of the department of surgery at University of California at Los Angeles, and colleagues wrote.

Pleomorphic liposarcoma is an aggressive form of soft tissue sarcoma. Surgery is the only potentially curative therapy; however, the impact of surgical margins on survival has been the subject of extensive debate.

Previous studies — including one that included 37 patients and a median follow-up of 38 months — did not confirm a correlation between microscopic tumor after resection and longer OS, according to study background.

Crompton and colleagues conducted their study to assess whether surgical resection margins correlated with long-term survival.

Researchers analyzed data from 39 patients (median age, 62 years; range, 22-88; 30 men) included in the prospectively maintained UCLA Sarcoma Database. All patients received treatment for histologically confirmed pleomorphic liposarcoma at UCLA’s sarcoma program from 1995 to 2015.

Tumor locations included lower extremity (44%), upper extremity (26%), trunk (18%) and retroperitoneum (10%). Median tumor size was 10 cm (range, 1.5-25).

Median follow-up was 8.52 years.

Patients with R0 resection achieved longer median OS than those with R1 resection (10.14 years vs. 4.27 years; HR = 2.95; 95% CI, 1.04-8.35).

Twenty-three patients received chemotherapy; however, chemotherapy receipt did not improve survival (HR = 1.97; 95% CI, 0.59-6.54). – by Mark Leiser

 For more information:

Niu X, et al. Abstract 2784460. Presented at: Connective Tissue Oncology Society Annual Meeting; Nov. 8-11, 2017; Maui.

 Disclosures: The authors report no relevant financial disclosures.